AbstractBreast cancer cells develop resistance to endocrine therapies by shifting between estrogen receptor (ER)-regulated and growth factor receptor (GFR)-regulated survival signaling pathways. To study this switch, we propose a mathematical model of crosstalk between these pathways. The model explains why MCF7 sub-clones transfected with HER2 or EGFR show three GFR-distribution patterns, and why the bimodal distribution pattern can be reversibly modulated by estrogen. The model illustrates how transient overexpression of ER activates GFR signaling and promotes estrogen-independent growth. Understanding this survival-signaling switch can help in the design of future therapies to overcome resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer. Endocrin...
Breast cancer, the main cancer in women, occurs in approximately 27% of all yearly diagnosed cancer ...
Estrogen receptor α (ER) is the major driver of ∼75% of breast cancers, and multiple ER targeting dr...
AbstractBreast cancer cells develop resistance to endocrine therapies by shifting between estrogen r...
Breast cancer evolution and tumor progression are governed by the complex interactions between stero...
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes...
168 pagesOutcomes from recent studies have led to the development of novel therapeutic treatments fo...
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes...
Summarization: The importance of ErbB receptor signaling in breast cancer is consistent with its fun...
Estrogen receptor (ER) has a crucial role in normal breast development and is expressed in the most ...
The majority of breast cancer cases are dependent on estrogen signaling, which is why endocrine ther...
The estrogen receptor (ER) is expressed in approximately 70% of sporadic breast cancers and is belie...
<p>A mechanism begins by the cell signals (represented by stars) transduction through trans-membrane...
In this article, we focus on the subtype of estrogen receptor (ER)-positive, human epidermal growth ...
The importance and role of the estrogen receptor (ER) pathway has been well-documented in both breas...
Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer. Endocrin...
Breast cancer, the main cancer in women, occurs in approximately 27% of all yearly diagnosed cancer ...
Estrogen receptor α (ER) is the major driver of ∼75% of breast cancers, and multiple ER targeting dr...
AbstractBreast cancer cells develop resistance to endocrine therapies by shifting between estrogen r...
Breast cancer evolution and tumor progression are governed by the complex interactions between stero...
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes...
168 pagesOutcomes from recent studies have led to the development of novel therapeutic treatments fo...
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes...
Summarization: The importance of ErbB receptor signaling in breast cancer is consistent with its fun...
Estrogen receptor (ER) has a crucial role in normal breast development and is expressed in the most ...
The majority of breast cancer cases are dependent on estrogen signaling, which is why endocrine ther...
The estrogen receptor (ER) is expressed in approximately 70% of sporadic breast cancers and is belie...
<p>A mechanism begins by the cell signals (represented by stars) transduction through trans-membrane...
In this article, we focus on the subtype of estrogen receptor (ER)-positive, human epidermal growth ...
The importance and role of the estrogen receptor (ER) pathway has been well-documented in both breas...
Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer. Endocrin...
Breast cancer, the main cancer in women, occurs in approximately 27% of all yearly diagnosed cancer ...
Estrogen receptor α (ER) is the major driver of ∼75% of breast cancers, and multiple ER targeting dr...